Applications
Online Inquiry
For research use only. Not intended for any clinical use.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Non-Human Primate (NHP) Application in Cytokine Release Syndrome (CRS) Modeling
Are you currently facing complex clinical trials, unpredictable patient toxicity, or increasing regulatory scrutiny of novel immunotherapies? Creative Biolabs' NHP helps you de-risk your cell therapy candidate, predict clinical outcomes, and secure IND success through clinically-relevant Non-Human Primate models for immuno-oncology.
Precision Safety for Cell Therapies by Using Our NHPs
NHP models provide essential translational data for predicting and mitigating life-threatening CRS and associated neurotoxicity (ICANS).
Overview of NHP Applications in Cell Therapy
What Are Our Research Areas?
The global revolution in adoptive T-cell therapies, including CAR-T cells and T-cell engaging bispecifics, delivers unparalleled therapeutic efficacy in hematologic malignancies and increasingly in solid tumors. However, this potent immune activation is frequently accompanied by severe, sometimes fatal, systemic inflammation known as CRS, and its complex neurological manifestation, ICANS. Developing therapeutic agents to manage or prevent these toxicities requires a comprehensive understanding of the underlying pathobiology—specifically, the mechanisms of systemic cytokine storm generation, blood-brain barrier (BBB) disruption, and T-cell trafficking into the central nervous system (CNS). Preclinical research must accurately model the entire spectrum of this multi-organ inflammatory cascade to ensure patient safety and regulatory compliance.
Why Choose Us?
NHPs offer the critical biological fidelity needed to predict CRS and ICANS severity in human patients. Creative Biolabs leverages these advantages:
- Genetic and Immunological Similarity: NHPs possess a highly conserved immune system, receptor repertoire, and cytokine profile that closely mirrors human response kinetics, unlike rodent models.
- Clinical Translational Relevance: NHP models, uniquely, faithfully recapitulate the full clinical syndrome of CRS and ICANS (e.g., fever, elevated CRP, neurological symptoms, as demonstrated by leading clinical studies).
- Complex System Modeling: NHPs allow for the analysis of systemic, multi-organ effects, including direct evaluation of the BBB integrity and cytokine gradients between the systemic circulation (serum) and the CNS (CSF).
- Physiological Tissue Distribution: Accurate modeling of tissue and organ distribution, crucial for predicting both efficacy and off-target toxicity.
Fig.1 Pathophysiology of ICANS.1
Key Applications
Creative Biolabs' NHP platform provides mechanistic data crucial for de-risking your cell therapy program. Inquire today to discuss a tailored study design.
- Modeling Severe CRS: NHP models allow for the high-resolution, longitudinal tracking of systemic inflammatory markers, including CRP, Ferritin, and the key cytokine cascade, which are directly predictive of human clinical CRS severity. This permits early assessment of peak toxicity kinetics and duration.
- Elucidating Neurotoxicity (ICANS) Pathobiology: NHPs are essential for mechanistic understanding, confirming that neurotoxicity is mediated by T-cell activation and inflammation, rather than solely antigen presence. Studies show that CAR T-cells infiltrate the brain parenchyma following BBB disruption, correlating directly with adverse neurological symptoms.
- Evaluating Toxicity Mitigation Strategies: The model provides a functional testbed for prophylactic or interventional strategies to prevent or abort severe CRS and ICANS before clinical translation.
- Determining Translational Safety and Pharmacodynamics (PD): NHPs allow for the establishment of clinically relevant No Observed Adverse Effect Levels and Maximum Tolerated Doses, directly linking infused cell dose to expansion kinetics, target engagement, and toxicity onset for robust translational safety packages.
How Do Creative Biolabs Support Your Projects?
Creative Biolabs provides an end-to-end suite of services specifically designed to capture the complexity of CAR T-cell safety and disposition in NHPs.
| Service Capability | Corresponding Application Area |
| Cytokine/Chemokine Multiplex Assays | Our high-sensitivity, multiplexed assays simultaneously measure dozens of inflammatory mediators, including critical markers like IL-6 and GM-CSF, essential for characterizing the CRS profile. |
| CSF & Other Body Fluids Collection | Specialized NHP procedures allow for safe, serial sampling, providing the unique data required to track localized cytokine gradients and T-cell accumulation. |
| Large Molecule Quantitation (ELISA, MSD) | Accurate, sensitive quantitation of CAR T-cell persistence and expansion in blood and tissue samples is performed using validated platforms. |
| ADA & Neutralizing Antibody (NAb) Assays | We screen for ADA and NAb against the CAR construct to predict and understand potential loss of efficacy or altered toxicity profiles. |
Translational Impact
Partnering with Creative Biolabs dramatically reduces the inherent risk associated with first-in-human cell therapy trials. Our NHP modeling data provides unparalleled fidelity, moving beyond simple proof-of-concept. The NHP data showing T-cell infiltration and CSF cytokine profiles provides the mechanistic evidence required to satisfy critical regulatory queries regarding ICANS risk. This leads to early detection of immune responses and toxicity mechanisms, resulting in reduced risk of IND failure and more informed clinical trial design. This mechanistic clarity enables the precise identification of patient exclusion criteria and the strategic deployment of toxicity mitigation agents, saving time and capital.
Frequently Asked Questions
Q: How does Creative Biolabs ensure data quality and sensitivity for cytokine profiling during peak CRS?
A: We utilize high-sensitivity multiplex and ultrasensitive immunoassay technologies that require minimal sample volumes while supporting cytokine detection in the low picogram/mL range. Our assays are validated using relevant NHP matrices, including serum and CSF, to provide reliable cytokine profiling during periods of heightened immune activation.
Q: What unique sample collections are possible in the NHP model that directly address ICANS/Neurotoxicity?
A: Unlike smaller models, the NHP platform allows for safe, serial, and longitudinal collection of Cerebrospinal Fluid (CSF). This is vital because the cytokine profile in the CSF (e.g., IL-6, IL-2) is often disproportionately high compared to serum, providing the true mechanistic link to neurotoxicity.
Q: How can NHP CRS modeling provide a clearer prediction of clinical outcome than humanized mouse models?
A: While humanized mouse models are useful, they lack the native, fully immunocompetent human-like endothelium and BBB structure. NHPs develop a multi-system inflammatory response and T-cell trafficking that perfectly mimics the human clinical syndrome of CRS and ICANS, making the translational prediction of dose and toxicity mechanism significantly more reliable.
Q: What precautions do you take to accurately monitor and track neurological symptoms in the NHP models?
A: Neurotoxicity is a critical endpoint. Our protocols involve continuous, standardized behavioral assessments and neurological scoring, often supplemented by advanced clinical diagnostics like MRI/PET scans and, the ability to track the upregulation of T-cell trafficking markers on infiltrating T-cells.
Q: What is the typical turnaround time for receiving the full safety report package, including PK/TK and immunotoxicity data?
A: While complex studies are project-dependent, we prioritize rapid data delivery. Our integrated Bioanalysis & Biomarker lab works in parallel with the in-life phase. We aim to deliver a comprehensive, regulatory-ready report summarizing CAR T-cell expansion, CRS kinetics, and all associated bioanalysis data within 6–8 weeks post-study completion.
Contact Us
Creative Biolabs offers unparalleled expertise in translational immuno-oncology, providing validated NHP models and specialized bioanalytical services required to de-risk your most advanced cell therapy assets. Contact us and leverage our Creative Biolabs NHP for your next cell therapy safety study.
Reference
- Arvanitis, Panos, et al. "Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations." Current Oncology 32.4 (2025): 198. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/curroncol32040198